Literature DB >> 7655312

Measuring substance abuse program treatment orientations: the Drug and Alcohol Program Treatment Inventory.

R W Swindle1, K A Peterson, M J Paradise, R H Moos.   

Abstract

Assessment of therapeutic orientation is a significant problem in substance abuse program evaluation. This study reports the initial results of a new approach to measuring treatment orientation through a self-report survey that focuses on distinctive features of substance abuse treatment orientations. The Drug and Alcohol Program Treatment Inventory (DAPTI) assesses treatment goals and activities specific to eight orientations: AA/12 Step, Therapeutic Community, Cognitive-Behavioral, Insight/Psychodynamic, Rehabilitation, Dual Diagnosis, Medical and Marital/Family Systems. We present findings from a nationwide assessment of 327 Veterans Administration (VA) Substance Abuse treatment programs that demonstrate promising subscale internal consistency, discriminant validity, and concurrent validity. In addition, the DAPTI distinguishes between programs with independently verified orientations and between inpatient, extended care, outpatient, and methadone maintenance programs. The DAPTI may be helpful in systematically assessing differences in treatment orientations between different types of programs, such as inpatient, community residential, and outpatient care.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7655312     DOI: 10.1016/0899-3289(95)90306-2

Source DB:  PubMed          Journal:  J Subst Abuse        ISSN: 0899-3289


  17 in total

1.  Influence of religiosity on 12-step participation and treatment response among substance-dependent adolescents.

Authors:  John F Kelly; Maria E Pagano; Robert L Stout; Shannon M Johnson
Journal:  J Stud Alcohol Drugs       Date:  2011-11       Impact factor: 2.582

2.  Youth recovery contexts: the incremental effects of 12-step attendance and involvement on adolescent outpatient outcomes.

Authors:  John F Kelly; Karen Urbanoski
Journal:  Alcohol Clin Exp Res       Date:  2012-04-17       Impact factor: 3.455

Review 3.  Theory-based active ingredients of effective treatments for substance use disorders.

Authors:  Rudolf H Moos
Journal:  Drug Alcohol Depend       Date:  2006-11-28       Impact factor: 4.492

4.  Longitudinal associations between fathers' heavy drinking patterns and children's psychosocial adjustment.

Authors:  Jasmina Burdzovic Andreas; Timothy J O'Farrell
Journal:  J Abnorm Child Psychol       Date:  2007-02

5.  Program structure, staff perceptions, and client engagement in treatment.

Authors:  Kirk M Broome; Patrick M Flynn; Danica K Knight; D Dwayne Simpson
Journal:  J Subst Abuse Treat       Date:  2007-04-16

6.  Organizational characteristics of drug abuse treatment programs for offenders.

Authors:  Christine E Grella; Lisa Greenwell; Michael Prendergast; David Farabee; Elizabeth Hall; Jerome Cartier; William Burdon
Journal:  J Subst Abuse Treat       Date:  2007-03-09

7.  Brief family treatment intervention to promote aftercare among male substance abusing patients in inpatient detoxification: A quasi-experimental pilot study.

Authors:  Timothy J O'Farrell; Marie Murphy; Jane Alter; William Fals-Stewart
Journal:  Addict Behav       Date:  2007-01-16       Impact factor: 3.913

8.  Randomized clinical trial of matching client alcohol use disorder severity and level of cognitive functioning to treatment setting: A partial replication and extension.

Authors:  Robert G Rychtarik; Neil B McGillicuddy; George D Papandonatos; Robert B Whitney; Gerard J Connors
Journal:  Psychol Addict Behav       Date:  2017-02-02

Review 9.  Policy-relevant program evaluation in a national substance abuse treatment system.

Authors:  K Humphreys; E G Hamilton; R H Moos; R T Suchinsky
Journal:  J Ment Health Adm       Date:  1997

10.  Smoking Cessation and Adolescent Treatment Response With Comorbid ADHD.

Authors:  Maria E Pagano; Christina M Delos-Reyes; Sherry Wasilow; Kathleen M Svala; Steven P Kurtz
Journal:  J Subst Abuse Treat       Date:  2016-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.